← Leaderboards
Markus Y Mapara
University Of Pittsburgh At Pittsburgh
$4,382,674
Attributed
$7,950,059
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2008–25$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,950,059 · 4
By mechanism
R01$6,935,012 · 3
T32$1,015,047 · 1
Top collaborators
- Jing Fu5 shared
- Suzanne Lentzsch5 shared
- Milan N Stojanovic4 shared
- Katherine D Crew2 shared
- Dawn Hershman2 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Nicole E Scharping$450,509
- Mark Eugene Snyder$3,068,056
- Edwin K Jackson$26,285,581
- Theresa L. Whiteside$29,550,469
- Louis D Falo$30,012,458
Others in their field
Top investigators on “Signal Transduction”
- Peter B. Gilbert · Fred Hutchinson Cancer Center$148,539,615
- David Heimbrook · Leidos Biomedical Research, Inc.$82,049,940
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$70,290,471
- Garret A Fitzgerald · University Of Pennsylvania$66,142,222
- Michael Barry Kastan · Duke University$64,512,357
- Randall J Bateman · Washington University$62,939,456
Research focus
Signal TransductionT-LymphocyteIn VivoMediatingPlayAntigen-Presenting CellsPathway InteractionsIn VitroMalignant NeoplasmsSignal PathwayMultiple MyelomaBaseCellsPreventMolecularReactionHematopoieticAllogenicHematopoietic Stem Cell TransplantationMouse ModelStructureBehavior TherapyCell SurvivalBone Marrow Transplantation
Grant awards (16)
Molecular Oncology Training Program$531,167
T32 · FY2025 · CA
Binding of MMP13 to Immune Checkpoint Receptor PD-1H links Bone Disease with Immune Suppression in Multiple Myeloma$478,447
R01 · FY2025 · CA
Molecular Oncology Training Program$483,880
T32 · FY2024 · CA
Binding of MMP13 to Immune Checkpoint Receptor PD-1H links Bone Disease with Immune Suppression in Multiple Myeloma$454,526
R01 · FY2024 · CA
Binding of MMP13 to Immune Checkpoint Receptor PD-1H links Bone Disease with Immune Suppression in Multiple Myeloma$468,878
R01 · FY2023 · CA
Binding of MMP13 to Immune Checkpoint Receptor PD-1H links Bone Disease with Immune Suppression in Multiple Myeloma$469,148
R01 · FY2022 · CA
Graft Engineering of Allogeneic Hematopoietic Stem Cell Products with Molecular Cascades$646,892
R01 · FY2021 · EB
Binding of MMP13 to Immune Checkpoint Receptor PD-1H links Bone Disease with Immune Suppression in Multiple Myeloma$494,221
R01 · FY2021 · CA
Graft Engineering of Allogeneic Hematopoietic Stem Cell Products with Molecular Cascades$665,709
R01 · FY2020 · EB
Graft Engineering of Allogeneic Hematopoietic Stem Cell Products with Molecular Cascades$656,925
R01 · FY2019 · EB
Graft Engineering of Allogeneic Hematopoietic Stem Cell Products with Molecular Cascades$658,221
R01 · FY2018 · EB
Role of STAT1 and STAT3 in Graft versus Host Disease and Graft versus Leukemia Ef$409,730
R01 · FY2012 · HL · contact PI
Role of STAT1 and STAT3 in Graft versus Host Disease and Graft versus Leukemia Ef$379,877
R01 · FY2011 · HL · contact PI
Role of STAT1 and STAT3 in Graft versus Host Disease and Graft versus Leukemia Ef$379,866
R01 · FY2010 · HL · contact PI
Role of STAT1 and STAT3 in Graft versus Host Disease and Graft versus Leukemia Ef$379,854
R01 · FY2009 · HL · contact PI
Role of STAT1 and STAT3 in Graft versus Host Disease and Graft versus Leukemia Ef$392,718
R01 · FY2008 · HL · contact PI